Factors determining penetrance in familial atypical haemolytic uraemic syndrome

被引:25
|
作者
Sansbury, Francis H. [1 ,2 ,3 ]
Cordell, Heather J. [4 ]
Bingham, Coralie [2 ,5 ]
Bromilow, Gilly [1 ]
Nicholls, Anthony [5 ]
Powell, Roy [6 ]
Shields, Bev [2 ]
Smyth, Lucy [5 ]
Warwicker, Paul [7 ]
Strain, Lisa [8 ]
Wilson, Valerie [8 ]
Goodship, Judith A. [4 ]
Goodship, Timothy H. J. [4 ]
Turnpenny, Peter D. [1 ,2 ]
机构
[1] Royal Devon & Exeter Hosp Heavitree, Royal Devon & Exeter NHS Fdn Trust, Peninsula Clin Genet Serv, Exeter, Devon, England
[2] Univ Exeter, Sch Med, Exeter, Devon, England
[3] St Michaels Hosp, Univ Hosp Bristol NHS Fdn Trust, Bristol Clin Genet Serv, Bristol, Avon, England
[4] Newcastle Univ, Inst Med Genet, Newcastle Upon Tyne NE1 3BZ, Tyne & Wear, England
[5] Royal Devon & Exeter Hosp Wonford, Royal Devon & Exeter NHS Fdn Trust, Dept Renal Med, Exeter, Devon, England
[6] Royal Devon & Exeter Hosp Wonford, Royal Devon & Exeter NHS Fdn Trust, Res Design Serv South West, Exeter, Devon, England
[7] East & North Hertfordshire NHS Trust, Lister Renal Units, Stevenage, Herts, England
[8] Newcastle Upon Tyne Hosp NHS Fdn Trust, Northern Mol Genet Serv, Newcastle Upon Tyne, Tyne & Wear, England
基金
英国医学研究理事会;
关键词
COMPLEMENT FACTOR-H; MULTILOCUS LINKAGE ANALYSIS; MEMBRANE COFACTOR PROTEIN; GENE-MUTATIONS; DISEASE; RECOGNITION; CFH; SUSCEPTIBILITY; PREDISPOSE; CANCER;
D O I
10.1136/jmedgenet-2014-102498
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Background Inherited abnormalities of complement are found in similar to 60% of patients with atypical haemolytic uraemic syndrome (aHUS). Such abnormalities are not fully penetrant. In this study, we have estimated the penetrance of the disease in three families with a CFH mutation (c.3643C>G; p. Arg1215Gly) in whom a common lineage is probable. 25 individuals have been affected with aHUS with three peaks of incidence-early childhood (n=6), early adulthood (n= 11) and late adulthood (n= 8). Eighteen individuals who have not developed aHUS carry the mutation. Methods We estimated penetrance at the ages of 4, 27, 60 and 70 years as both a binary and a survival trait using MLINK and Mendel. We genotyped susceptibility factors in CFH, CD46 and CFHR1 in affected and unaffected carriers. Results and Conclusions We found that the estimates of penetrance at the age of 4 years ranged from <0.01 to 0.10, at the age of 27 years from 0.16 to 0.29, at the age of 60 years from 0.39 to 0.51 and at the age of 70 years from 0.44 to 0.64. We found that the CFH haplotype on the allele not carrying the CFH mutation had a significant effect on disease penetrance. In this family, we did not find that the CD46 haplotypes had a significant effect on penetrance.
引用
收藏
页码:756 / 764
页数:9
相关论文
共 50 条
  • [21] Correction to: Ravulizumab: A Review in Atypical Haemolytic Uraemic Syndrome
    Yahiya Y. Syed
    Drugs, 2021, 81 : 1363 - 1364
  • [22] OUTCOMES IN PATIENTS DIAGNOSED WITH ATYPICAL HAEMOLYTIC URAEMIC SYNDROME
    Walker, Emma Y. X.
    Marks, Stephen D.
    Waters, Aoife
    PEDIATRIC NEPHROLOGY, 2021, 36 (10) : 3400 - 3400
  • [23] Pregnancy-induced atypical haemolytic uraemic syndrome
    Edwards, Gwenno M.
    Notzing, Jessica
    Frost, Paul
    Pyart, Rhodri
    CLINICAL MEDICINE, 2021, 21 (04) : E403 - E404
  • [24] Early treatment with eculizumab in atypical haemolytic uraemic syndrome
    Garjau, Maria
    Azancot, Maria
    Ramos, Rosa
    Sanchez-Corral, Pilar
    Angeles Montero, Maria
    Seron, Daniel
    CLINICAL KIDNEY JOURNAL, 2012, 5 (01) : 31 - 33
  • [25] Atypical haemolytic uraemic syndrome in a child with cystic fibrosis
    Wong, Matthew D.
    Patel, Chirag
    McTaggart, Steven
    Wainwright, Claire E.
    JOURNAL OF PAEDIATRICS AND CHILD HEALTH, 2022, 58 (03) : 532 - 535
  • [26] Malignancy and thrombotic microangiopathy or atypical haemolytic and uraemic syndrome?
    Favre, Guillaume A.
    Touzot, Maxime
    Fremeaux-Bacchi, Veronique
    Hyvernat, Herve
    Gueffet, Jean-Pierre
    Rohrlich, Pierre S.
    Queyrel, Viviane
    Esnault, Vincent
    Fakhouri, Fadi
    BRITISH JOURNAL OF HAEMATOLOGY, 2014, 166 (05) : 802 - 805
  • [27] Eculizumab for atypical haemolytic uraemic syndrome: what next?
    Fadi Fakhouri
    Véronique Frémeaux-Bacchi
    Nature Reviews Nephrology, 2013, 9 : 495 - 496
  • [28] Complement therapy in atypical haemolytic uraemic syndrome (aHUS)
    Wong, Edwin K. S.
    Goodship, Tim H. J.
    Kavanagh, David
    MOLECULAR IMMUNOLOGY, 2013, 56 (03) : 199 - 212
  • [29] Atypical haemolytic uraemic syndrome associated with a hybrid complement gene
    Venables, Julian P.
    Strain, Lisa
    Routledge, Danny
    Bourn, David
    Powell, Helen M.
    Warwicker, Paul
    Diaz-Torres, Martha L.
    Sampson, Anne
    Mead, Paul
    Webb, Michelle
    Pirson, Yves
    Jackson, Michael S.
    Hughes, Anne
    Wood, Katrina M.
    Goodship, Judith A.
    Goodship, Timothy H. J.
    PLOS MEDICINE, 2006, 3 (10) : 1957 - 1967